In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

The poster presented data from AUTX-703, a potent, selective and orally bioavailable heterobifunctional degrader of KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

an AURIGIN-identified histone acetyltransferase driving small cell lung cancer (SCLC) and other tumor types. In a series of experiments, Auron showed that treatment with AUTX-703 potently degraded ...